| 36.91 Delayed Data As of Sep 20 |  +1.43 / +4.03%Today’s Change | 27.75 Today|||52-Week Range 46.65 | +2.07% Year-to-Date |
| Previous close | 35.48 |
| Today’s open | 35.49 |
| Day’s range | 35.25 - 37.44 |
| Volume | 1,471,665 |
| Average volume (3 months) | 482,031 |
| Market cap | $2.0B |
| Earnings growth (last year) | -24.31% |
| Earnings growth (this year) | +103.89% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +13.70% |
| P/E ratio | 42.9 |
| Price/Sales | 48.04 |
| Price/Book | 3.82 |
| Today’s change | Today’s % change | |
|---|---|---|
| QUREUniqure NV | -0.93 | -1.96% |
| XLRNAcceleron Pharma Inc | -0.19 | -0.44% |
| ZLABZai Lab Ltd | +0.48 | +1.40% |
| DCPHDeciphera Pharmaceut... | +0.51 | +1.42% |
| Next reporting date | November 11, 2019 |
| EPS forecast (this quarter) | -$0.55 |
| Annual revenue (last year) | $40.6M |
| Annual profit (last year) | -$70.4M |
| Net profit margin | -173.41% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Bassil I. Dahiyat |
Chief Financial Officer & Senior Vice President John J. Kuch |
Corporate headquarters Monrovia, California |
